1 of 1
Story summary
- Abbott Laboratories announced on November 20, 2025 that it will acquire Exact Sciences for about $21 billion in cash at $105 per share, a 22% premium.
- The deal includes Exact Sciences' colorectal cancer test Cologuard and breast cancer test Oncotype DX, expanding Abbott's cancer-screening footprint.
- Analysts question the strategic fit, noting Abbott lacks an oncology division.
- The deal is expected to close in Q2 2026, pending shareholder approval.
